Tuveson Lab Walks for a Cure

October 6, 2019

Today, the Tuveson Lab participated in the 19th annual Long Island Pancreatic Cancer Research Walk. The walk, which is organized by the Lustgarten Foundation, helps to raise money to support pancreatic cancer research. More than 7000 people donned purple shirts and joined the walk this year, which raised more than $1 million. In addition to walking, members of the Tuveson Lab manned our information table where walk participants could come to ask questions about pancreatic cancer research.

Congratulations to Fieke on the publication of her paper!

September 16, 2019

Congratulations to Tuveson Lab Clinical Fellow Fieke Froeling on the publication of her new paper in Clinical Cancer Research! Fieke and team collaborated with Boston Biomedical, Inc. to better understand the mechanism of their anti-cancer drug napabucasin (BBI-608). The team discovered that this drug can serve as a substrate for intracellular oxidoreductases, such as NQO1. By serving as a substrate for NQO1, the drug promotes the production of oxidants, which damage DNA and prove toxic to pancreatic cancer cells. The team uncovered a network of cellular pathways affected by treatment with napabucasin (see figure below). By better understanding how napabucasin works the researchers hope to be able to rationally design therapeutic combinations involving napabucasin that are more effective at treating pancreatic cancer than current therapies.

Congrats to Young Park and Mariano Ponz-Sarvise on their recent paper!

September 9, 2019

Congratulations to Young Park, Mariano Ponz-Sarvise, and other present and former members of the Tuveson Lab on the publication of their study in Clinical Cancer Research today. Young and Mariano studied whether the MAPK and AKT pathways, activated downstream of mutant KRAS, could be inhibited together to target pancreatic cancer cells. They encountered a problem well-known to cancer researchers, which is that cancer cells find ways to circumvent the targeting of these pathways allowing them to resist therapies. By comparing non-cancerous organoids to pancreatic cancer organoids, they discovered a mechanism specifically used by the cancer cells to escape MAPK/AKT co-inhibition: the cancer cells specifically activate members of the ERBB pathway. Adding a therapy that blocks ERBB activation prevented cancer cells from using this mechanism to escape. Their results suggest that novel combination treatments that include a pan-ERBB inhibitor may be more effective for treating pancreatic cancer, provided the side effects of these combinations are tolerable.

See the recent CSHL press release for more information.

New lab technicians join the Tuveson Lab

August 23, 2019

It has been a busy couple of months in the Tuveson Laboratory, with the addition of three new lab technicians. Zachary Galluzzo joins our Human Organoid Team, where he will help to generate patient-derived organoid models of cancer and help to launch the new CSHL Organoid Shared Resource. Ashley Adler and Abhishek (Abhi) Doshi join our Preclinical Team, where they will aid in our animal studies. Shown below is our Preclinical Team (from left to right: Ashley, Matt, Abhi, and Erin) working to together on a recent afternoon to get each other up to speed on our protocols and record-keeping.

Tuveson Lab Technician Melissa Yao departs to start her Master’s studies

July 26, 2019

Today, members of the Tuveson Lab bid a fond farewell to senior Tuveson Lab technician Melissa Yao. Melissa joined the lab in 2016, shortly after finishing her undergraduate studies at Stony Brook University. Melissa quickly mastered the lab’s organoid and animal protocols and was instrumental in helping to organize and teach the official CSHL Organoid Course in December 2016. She became a leader in the laboratory, helping others to get oriented, keeping the laboratory organized, and helping new lab members learn key techniques. She developed many close friendships in the lab, including with Research Investigator Young Park; the two are shown twinning below. Many members of the Tuveson Lab also benefited from Melissa’s crochet talents. Melissa leaves us to get a Master’s degree at the Icahn School of Medicine at Mount Sinai. We wish her all the best in her studies and beyond!

Congratulations to Georgi Yordanov on the successful defense of his thesis!

July 3, 2019

Congratulations to Tuveson Lab grad student Georgi Yordanov on the successful defense of his Ph.D. thesis. Georgi studied the role of two transcription factors, Myc and Spdef in promoting pancreatic cancer development. His thesis studies demonstrated that Spdef aids pancreatic cancer cells by helping to mitigate proteotoxic stress. Other members of the Tuveson Lab will now continue Georgi’s studies into the links between proteotoxic stress and pancreatic cancer. Dr. Yordanov will soon be leaving the Tuveson Lab to apply his science acumen to Wall Street, where he will take a position as an Equity Research Associate at Cowen and Company. We wish him all the best in his future endeavors!

Congrats to former Tuveson Lab member Dannie Engle on her new paper, out today in Science!

June 20, 2019

Congratulations to Dannie Engle on the publication  of her postdoctoral research in Science today. Dannie studied the glycosylation mark CA19-9. This sugar is present in proteins in the bloodstream of 75% of pancreatic cancer patients, but its potential functions are poorly understood. Studying this sugar has been challenging because mice do not produce it. Dannie engineered mice to inducibly produce CA19-9. Surprisingly, turning on CA19-9 production in the mice caused pancreatitis, an inflammatory condition of the pancreas known to increase the risk of developing pancreatic cancer. Moreover, CA19-9 production worsened the pancreatic tumors and decreased the survival of a mouse model of pancreatic cancer. These effects could be reversed using an antibody that blocked the sugar. Together, Dannie’s results suggest that rather than being simply a biomarker of pancreatic cancer, CA19-9 has a direct role in promoting this aggressive disease. Prophylactic intervention to block CA19-9 in the setting of recurrent pancreatitis in patients might help to reduce the severity of pancreatitis and to prevent the development of pancreatic cancer.

See the recent CSHL press release for more information.

Congratulations to Ela on the publication of her paper!

June 13, 2019

Congratulations to Ela Elyada on the publication of her new paper in Cancer Discovery. Ela collaborated with Dr. Paul Robson, an expert in single cell approaches at Jackson Laboratory. They used single-cell RNA-sequencing to characterize cell populations present in pancreatic tumors, with a special focus on the cancer-associated fibroblasts. Excitingly, they discovered a new type of fibroblast present in pancreatic tumors, that is capable of antigen presentation.
For more information, see the CSHL press release.

The Tuveson Lab Opens Up for the CSHL Open House

June 8, 2019

Members of the Tuveson Laboratory participated in the CSHL Open House this weekend. This event brought more than 300 visitors to the CSHL Campus to learn about the research we conduct. Children and adults alike visited the Quick Building to see inside the Tuveson Lab, try multichannel pipetting, and play “histology detectives.”

The Tuveson Lab participates in Health Disparities Symposium

March 1, 2019

Members of the Tuveson Laboratory participated in a Cancer Health Disparities Symposium at SUNY Downstate today. We listened to interesting talks on cancer biology and on cancer health disparities. There was also a fantastic key note address from Alfred Lacks Carter, Jr., the grandson of Henrietta Lacks. Dennis presented the lab’s progress on our P20 project, which examines differences in pancreatic cancer biology in patients of different races.

The Tuveson Lab congratulates Ben on his last day

February 27, 2019

Today, the Tuveson Lab said goodbye to our talented technician Ben Spielman. We wish him good luck as he leaves us to pursue an M.D.-Ph.D. degree!

The Tuveson Lab commemorates World Pancreatic Cancer Day

November 15, 2018

Today, the Tuveson Lab gathered with the Lustgarten Foundation to commemorate World Pancreatic Cancer Day. This day seeks to raise awareness about pancreatic cancer and to promote progress towards curing this cancer.

Congrats to Giulia Biffi on the publication of her paper!

October 26, 2018

Dr. Biffi’s new paper is online today at Cancer Discovery! Following from the lab’s previous discovery that two different types of cancer associated fibroblasts (CAFs) co-exist in the pancreatic cancer microenvironment, Giulia sought to better understand the signaling cascades that specify each type of fibroblast’s fate. Her research has uncovered a role for IL-1 signaling in promoting the inflammatory CAF state found in stroma more distal to the cancer cells. In contrast, CAFs close to the cancer cells are exposed to cancer-secreted TGFβ which promotes downregulation of the IL-1 receptor, antagonizing IL1 signaling and promoting a myofibroblastic-CAF state. This study suggests new strategies to treat pancreatic tumors by targeting the inflammatory CAFs, which may prove more successful than treatments that target cancer cells alone.

See the recent CSHL press release for more information.

Tuveson Lab participates in research walk

October 9, 2018

Last weekend, the Tuveson Lab joined together to participate in the Lustgarten Foundation Pancreatic Cancer Research Walk. We worked together to raise money and awareness for this deadly cancer. At the walk, we also set up a research booth to talk to other walk participants about the research we do to find ways to diagnose pancreatic cancer sooner and identify better ways to target pancreas tumors.

Tuveson Lab goes fishing

August 9, 2018

Members of the Tuveson Lab put down their pipettes to go fishing today. The team went out east to Orient Point and boarded the vessel Brooklyn Girl. Sandra caught the biggest fish of the day, but many other lab members had good fishing luck, netting enough fish for a fish fry the next day.

Tuveson Lab hosts Junior Cancer Academy

July 19, 2018

Today, the first ever Tuveson Lab Junior Cancer Academy wrapped up. Six high school students joined us to learn about pancreatic cancer, basic biology, cancer research, and careers in science. Led by graduate student Georgi Yordanov, students learned to clone plasmids and perform immunohistochemical staining. Students presented their work to the lab during our weekly lab meeting. Summer undergrad Emily Ashkin also worked with Georgi to research the factors that drive expression of the transcription factor Spdef in pancreatic cancer cells. We wish our students all the best as they return to school this fall!

Best Wishes to Dr. Chang-Il Hwang and Eunjung Lee in Their New Lab!

June 29, 2018

Professor Hwang will be starting his own lab at U.C. Davis, and Eun will take a position as a Research Associate the Hwang Lab.

Stay tuned to the Hwang Lab Twitter Account for new developments!

Dr. Hervé Tiriac published his research showing organoids can be used to predict treatment response for pancreatic cancer patients

May 31, 2018

The lab’s newest paper is hot off the presses at Cancer Discovery. Hervé and other members of the Tuveson Lab generated and characterized a panel of organoid cultures from patients with pancreatic cancer. Organoids were treated with standard chemotherapies and targeted agents to determine the therapeutic response profile for each patient-derived organoid culture. By comparing drug sensitivities of the organoids to gene expression data, they were able to identify an organoid gene expression signature that predicts a response to chemotherapy.

See the recent CSHL press release for more information.

Congrats to Dr. Brinda Alagesan on her successful thesis defense!

April 25, 2018

Brinda successfully defended her thesis. Her research explored mitochondrial dynamics in pancreatic cancer cells. Dr. Alagesan will now return to medical school to complete her medical training.

Dr. Christine Chio starts her own lab as an Assistant Professor at Columbia University

November 1, 2017

Congrats to Professor Chio on her new position!

Dr. Michael Feigin published his work on recurrent non-coding mutations in PDAC

Large-scale exome sequencing efforts have revealed genes and pathways important for cancer progression. However, the exome comprises less than 2% of the human genome and whole-genome sequencing (WGS) analyses have revealed tumors often carry thousands of somatic mutations per genome, the vast majority of which are located in noncoding regions and are completely uncharacterized. To detect somatic noncoding mutations (NCMs) in pancreatic cancer (PDA), I co-developed a computational pipeline to analyze WGS data of 308 PDA tumors. To discriminate amongst the thousands of identified NCMs, we developed GECCO (Genomic Enrichment Computational Clustering Operation) to identify candidate NCMs that drive differential gene expression. Using GECCO, we identified novel recurrent mutations and interrogated expression data from matched tumors to find several variants associated with changes in mRNA levels. We found significant differential expression of 16 genes associated with NCMs, and reveal two (PTPRN2, SLC12A8) with previously unidentified clinical relevance in PDA. Pathway analysis of the genes associated with recurrent NCMs identified known and novel PDA pathways. Furthermore, we found enrichment for mutations in specific regulatory regions, suggesting that NCMs may be acted upon by selection during tumor formation. Our analysis provides a model for tumor evolution via the formation and selection for alterations in noncoding regulatory elements of specific genes as a means of control over specific biological pathways.

Tuveson lab at the NYC Science March

Sat, Apr 22, 2017

Dr. Abram Handly-Santana successfully defended his PhD thesis

Abram Handly-Santana was the first graduate student to join the Tuveson lab soon after our arrival at Cold Spring Harbor lab. Abram was part of the Watson School of Biological Sciences program – CSHL’s own graduate school. His work focused on the heterogeneity of the non-cancerous fibroblasts in pancreatic cancer and their role in supporting and restraining the growth of tumor cells. You can find out more about his exciting work in his paper or the recent CSHL press release.

NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer

Chio et al., Cell. 2016 Aug 11;166(4):963-76. doi: 10.1016/j.cell.2016.06.056. Epub 2016 Jul 28.

Christine Chio recently published her paper in Cell on the role of the transcription factor NRF2 in regulating protein translation in pancreatic cancer.

Link to Christine’s paper

You can find out more about her work and the field of redox here: